Statin Adverse Reaction Clinical Trial
Official title:
MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study
Statins are cornerstone treatment in secondary cardiovascular disease (CVD) prevention. Today, statin non-adherence (patients not taking their prescribed drug) remains a major public health concern, leading to adverse outcomes in terms of morbidity, mortality and healthcare costs. The principal reason for statin non-adherence and discontinuation is statin-associated muscle symptoms (SAMS). Objective SAMS diagnostics do not exist. We aim to unravel the pathophysiology of SAMS and develop diagnostic tools to differentiate real SAMS from muscle symptoms not related to the statin, among coronary patients with self-perceived SAMS. In this follow-up study we aims to determine the effect of 7 weeks open treatment with atorvastatin 40 mg/day, followed by 7 weeks open treatment with no lipid lowering treatment, on muscle symptom intensity in patients classified with confirmed statin-associated muscle symptoms (SAMS) (i.e. statin-dependent muscle side-effects) and non-SAMS in the MUscle Side-Effects of atorvastatin in coronary patients (MUSE) randomized double blinded cross-over trial. We have developed novel methods that will be used to measure atorvastatin metabolites and drug effect biomarkers directly in skeletal muscle and blood . The diagnostic accuracy of these biomarkers to differentiate real SAMS from non-SAMS will be evaluated. A new diagnostic tool may potentially be implemented to assess SAMS in the individual patient and enable personalized follow-up. It may also represent an important tool in the communication with patients misattributing their muscle symptoms to statins. The long-term results may be better quality of life and reduced morbidity, mortality and healthcare costs.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04986241 -
The Association of Statins on Cardiorespiratory Fitness and Exercise Adaptation
|
||
| Recruiting |
NCT04499859 -
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
|
Phase 4 | |
| Completed |
NCT03001076 -
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
|
Phase 3 | |
| Completed |
NCT02988115 -
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
|
Phase 3 | |
| Recruiting |
NCT05332158 -
Medicines Gaps Study
|
N/A | |
| Not yet recruiting |
NCT06381947 -
Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
|
Phase 4 | |
| Completed |
NCT03874156 -
MUscle Side-Effects of Atorvastatin in Coronary Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06262685 -
Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins
|
Phase 4 | |
| Completed |
NCT05806723 -
Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men
|
Phase 4 | |
| Active, not recruiting |
NCT03653663 -
NIRS to Diagnose SAMS
|
Phase 4 | |
| Completed |
NCT02993406 -
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
|
Phase 3 | |
| Recruiting |
NCT04069598 -
Statin Intolerance in Patients With Myocardial Infarction
|
||
| Terminated |
NCT04507373 -
7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events
|
Phase 4 |